Alzheimer’s Naltrexone
Inventor
Prof Ralph Martins, Centre of Excellence for Alzheimers Disease Research and Care
Applications
Pharmaceutical Industry.
IP status
Provisional patent filed.
Current status
Potential treatment via hormone modulation of beta amyloid production Preliminary data shows a trend towards a reduction in Aβ levels in patients following Naltrexone treatment. Reseach has identified another feature of Naltrexone in that it can reduce Aβ mediated toxicity in neuronal cell culture, suggesting that it can prevent Aβ-induced neuronal death.